Prabhav Kalaghatgi
Overview
Explore the profile of Prabhav Kalaghatgi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Maio N, Kalaghatgi P, Turakhia Y, Corbett-Detig R, Minh B, Goldman N
Nat Genet
. 2023 Apr;
55(5):746-752.
PMID: 37038003
Phylogenetics has a crucial role in genomic epidemiology. Enabled by unparalleled volumes of genome sequence data generated to study and help contain the COVID-19 pandemic, phylogenetic analyses of SARS-CoV-2 genomes...
2.
De Maio N, Kalaghatgi P, Turakhia Y, Corbett-Detig R, Minh B, Goldman N
bioRxiv
. 2022 Mar;
PMID: 35350209
Phylogenetics plays a crucial role in the interpretation of genomic data. Phylogenetic analyses of SARS-CoV-2 genomes have allowed the detailed study of the virus's origins, of its international and local...
3.
Kalaghatgi P, Pfeifer N, Lengauer T
Mol Biol Evol
. 2020 Feb;
37(6):1845.
PMID: 32011703
No abstract available.
4.
Knops E, Sierra S, Kalaghatgi P, Heger E, Kaiser R, Kalinina O
Genes (Basel)
. 2018 Jul;
9(7).
PMID: 29986475
Hepatitis C virus (HCV) causes a major health burden and can be effectively treated by direct-acting antivirals (DAAs). The non-structural protein 5A (NS5A), which plays a role in the viral...
5.
Palanisamy N, Kalaghatgi P, Akaberi D, Lundkvist A, Chen Z, Hu P, et al.
Antivir Ther
. 2018 May;
23(6):485-493.
PMID: 29745936
Background: HCV infections can now be completely cured, thanks to the currently marketed direct-acting antivirals (DAAs). It is known that HCV patients carry viral populations with baseline polymorphisms and/or mutations...
6.
Doring M, Buch J, Friedrich G, Pironti A, Kalaghatgi P, Knops E, et al.
Nucleic Acids Res
. 2018 May;
46(W1):W271-W277.
PMID: 29718426
Identifying resistance to antiretroviral drugs is crucial for ensuring the successful treatment of patients infected with viruses such as human immunodeficiency virus (HIV) or hepatitis C virus (HCV). In contrast...
7.
Neogi U, Siddik A, Kalaghatgi P, Gisslen M, Bratt G, Marrone G, et al.
Sci Rep
. 2017 Jul;
7(1):6371.
PMID: 28744024
A temporal increase in non-B subtypes has earlier been described in Sweden by us and we hypothesized that this increased viral heterogeneity may become a hotspot for the development of...
8.
Knops E, Schubel N, Heger E, Neumann-Fraune M, Kaiser R, Inden S, et al.
Clin Gastroenterol Hepatol
. 2016 Sep;
15(2):307-309.
PMID: 27670383
No abstract available.
9.
Kalaghatgi P, Pfeifer N, Lengauer T
Mol Biol Evol
. 2016 Jul;
33(10):2720-34.
PMID: 27436007
The widely used model for evolutionary relationships is a bifurcating tree with all taxa/observations placed at the leaves. This is not appropriate if the taxa have been densely sampled across...
10.
Kalaghatgi P, Sikorski A, Knops E, Rupp D, Sierra S, Heger E, et al.
PLoS One
. 2016 May;
11(5):e0155869.
PMID: 27196673
The face of hepatitis C virus (HCV) therapy is changing dramatically. Direct-acting antiviral agents (DAAs) specifically targeting HCV proteins have been developed and entered clinical practice in 2011. However, despite...